Genomes and Genes
brief psychiatric rating scale
Summary: A scale comprising 18 symptom constructs chosen to represent relatively independent dimensions of manifest psychopathology. The initial intended use was to provide more efficient assessment of treatment response in clinical psychopharmacology research; however, the scale was readily adapted to other uses. (From Hersen, M. and Bellack, A.S., Dictionary of Behavioral Assessment Techniques, p. 87)
Publications184 found, 100 shown here
- Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristicsJean A Frazier
Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, USA
J Am Acad Child Adolesc Psychiatry 46:979-88. 2007..We examined baseline demographic and clinical profiles of youths enrolled from 2001 to 2006 in the publicly funded multicenter, randomized controlled trial Treatment of Early-Onset Schizophrenia Spectrum Disorders...
- Remission in schizophrenia: proposed criteria and rationale for consensusNancy C Andreasen
Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA
Am J Psychiatry 162:441-9. 2005..These criteria should facilitate research and support a positive, longer-term approach to studying outcome in patients with schizophrenia...
- Relationship of dementia screening tests with biomarkers of Alzheimer's diseaseJames E Galvin
Alzheimer s Disease Research Centre, Washington University, St Louis, MO 63108, USA
Brain 133:3290-300. 2010....
- Factor structure of Bech's version of the Brief Psychiatric Rating Scale in Brazilian patientsJ A S Crippa
Departamento de Neurologia, , , , , SP, Brasil
Braz J Med Biol Res 35:1209-13. 2002The objective of the present study was to evaluate the factor structure of Bech's version of the Brief Psychiatric Rating Scale (BPRS), translated into Portuguese...
- [Assessment of the Life Skills Profile and the Brief Psychiatric Rating Scale as predictors of the length of psychiatric hospitalization]J Ballesteros Rodríguez
Fundación M feminine Josefa Recio Instituto de Investigaciones Psiquiátricas, Bilbao, Universidad del Pais Vasco, Leioa Bilbao, Spain
Actas Esp Psiquiatr 30:225-32. 2002..The aims of this study are to analyse the relationship between illness severity and adaptative behavior and to assess the predictive power of both constructs on the length of hospital stay...
- Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophreniaHirofumi Aki
Department of Psychiatry, Institute of Health Biosciences, The University of Tokushima Graduate School, 3 18 15 Kuramoto cho, Tokushima, Tokushima 770 8503, Japan
Psychiatry Res 158:19-25. 2008..Clinical symptoms were also assessed with several scales including the Brief Psychiatric Rating Scale (BPRS) and the Calgary Depression Scale for Schizophrenia (CDSS)...
- Subjective and objective measures of quality of life have different predictors for people with schizophreniaMasahito Tomotake
Department of Psychiatry, Institute of Health Biosciences, The University of Tokushima Graduate School, 3 18 15, Kuramoto Cho, Tokushimashi, Tokushima 770 8503, Japan
Psychol Rep 99:477-87. 2006..Psychiatric symptoms were also measured with the Brief Psychiatric Rating Scale and the Calgary Depression Scale for Schizophrenia...
- Symptom structure of acute mania: a factor study of the 24-item Brief Psychiatric Rating Scale in a national sample of patients hospitalized for a manic episodeAngelo Picardi
Italian National Institute of Health, Center of Epidemiology, Surveillance and Health Promotion, Mental Health Unit, Viale Regina Elena, 299 00161 Rome, Italy
J Affect Disord 108:183-9. 2008..Most studies included not only manic patients, but also patients with a mixed episode or other severe mental disorders. We aimed at further elucidating the symptom structure of manic states...
- Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective studyMatthew M Kurtz
Schizophrenia Rehabilitation Program, Neuropsychiatry Research Center, Institute of Living, 200 Retreat Avenue, Hartford, CT 06106, USA
Schizophr Bull 31:167-74. 2005..The significance of these findings for the development and assessment of novel treatment interventions for schizophrenia is discussed...
- Hospital comorbidity bias and the concept of schizophreniaMaarten Bak
Dept of Psychiatry and Neuropsychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University, Maastricht, The Netherlands
Soc Psychiatry Psychiatr Epidemiol 40:817-21. 2005..The direction of any dimensional comorbidity bias in psychotic illness was assessed in a longitudinal analysis of the psychopathology of patients assessed both inside and outside the hospital...
- Reliability of the interRAI suite of assessment instruments: a 12-country study of an integrated health information systemJohn P Hirdes
University of Waterloo, 200 University Ave W, Waterloo, ON N2L 3G1, Canada
BMC Health Serv Res 8:277. 2008..This study examined the reliability of the items from five instruments supporting home care, long term care, mental health, palliative care and post-acute care...
- Selection of outcome assessment instruments for inpatients with severe and persistent mental illnessGary M Burlingame
Brigham Young University, 238 TLRB, Provo, Utah 84602, USA
Psychiatr Serv 56:444-51. 2005..The limited resources associated with publicly funded inpatient facilities led to a recommendation to select at least one rater-completed and one patient-completed instrument...
- Consistency of Brief Psychiatric Rating Scale factor structure across a broad spectrum of schizophrenia patientsAlex Kopelowicz
David Geffen School of Medicine at University of California, Los Angeles, CA, USA
Psychopathology 41:77-84. 2008The Brief Psychiatric Rating Scale (BPRS) has been the workhorse of psychopathology assessment in studies of schizophrenia and related psychotic disorders for over 40 years...
- Factor structure and differential validity of the expanded Brief Psychiatric Rating ScaleAdrian Thomas
Department of Psychology, Auburn University, AL 36849, USA
Assessment 11:177-87. 2004The Brief Psychiatric Rating Scale (BPRS) is one of the most widely used measures in psychiatric outcome and clinical psychopharmacology research...
- The diagnostic accuracy of questions about past experiences of being mechanically restrained in a population of psychiatric patientsTuula Wallsten
University of Uppsala, Vasteras, Sweden
Memory 16:548-55. 2008..No clear relationship between psychiatric symptoms and reliability of self-reports was identified. The results highlight the subjective qualities of narratives about past experiences...
- Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating ScaleJ Ventura
UCLA Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA 90095 6968, USA
Psychiatry Res 97:129-35. 2000Previous four- and five-factor solutions of the 18-item Brief Psychiatric Rating Scale (BPRS) suggested the possibility of an affective dimension in psychosis...
- Stress and HPA-axis functioning in young people at ultra high risk for psychosisK N Thompson
PACE Clinic Orygen Research Centre, Locked Bag 10, Parkville 3052, Australia
J Psychiatr Res 41:561-9. 2007..These results indicate possible impairment in HPA-axis functioning in the early stages of psychotic illness, but further investigation of the relationships between these parameters is required...
- A real-life observational study of the effectiveness of FACT in a Dutch mental health regionMarjan Drukker
Department of Psychiatry and Neuropsychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University, PO Box 616, location Vijverdal 6200 MD Maastricht, The Netherlands
BMC Psychiatry 8:93. 2008..The effectiveness of FACT was compared with standard care, with a particular focus on possible moderating effects of patient characteristics within the case mix in FACT...
- Inter-rater reliability of the Brief Psychiatric Rating Scale and the Groningen Social Disabilities Schedule in a European multi-site randomized controlled trial on the effectiveness of acute psychiatric day hospitalsMatthias Schützwohl
Department of Psychiatry at Dresden University of Technology, Dresden, Germany
Int J Methods Psychiatr Res 12:197-207. 2003The objectives of this study were to report the inter-rater reliability of the Brief Psychiatric Rating Scale (BPRS 4...
- Comorbid anxiety disorders and divalproex sodium use among partial hospital patients with psychotic disordersMark H Townsend
Department of Psychiatry, LSU Health Sciences Center, New Orleans, LA 70112, USA
Compr Psychiatry 46:368-70. 2005..Each subject was diagnosed by structured interview, and 4 Brief Psychiatric Rating Scale (BPRS) items associated with agitation were assessed: anxiety, hostility, excitement, and tension...
- Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samplesKeith H Nuechterlein
UCLA Department of Psychiatry and Biobehavioral Sciences, 300 UCLA Medical Plaza, Room 2251, Los Angeles, CA 90095 6968, United States
Psychiatry Res 144:153-66. 2006....
- A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosisBenedicto Crespo-Facorro
University Hospital Marques de Valdecilla, Department of Psychiatry, Santander, Spain
J Clin Psychiatry 67:1511-21. 2006....
- Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trialHitoshi Takahashi
Yuri Kumiai General Hospital, Honjoh, Akita, Japan
J Clin Psychiatry 67:1577-82. 2006..The efficacy and safety of switching to olanzapine were investigated in patients with first-episode schizophrenia who failed to attain an adequate clinical response to an initial therapeutic trial of risperidone (2-6 mg/day for 12 weeks)...
- Risperidone dosing pattern and clinical outcome in psychosis: an analysis of 1713 casesChang Yoon Kim
Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
J Clin Psychiatry 66:887-93. 2005..To evaluate the outcome of different risperidone dosing strategies in clinical practice, we undertook a large, prospective, naturalistic study in which daily dosage was determined freely by local standards of care...
- A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illnessJames L Megna
Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA
J Psychiatr Pract 13:129-37. 2007..There is a paucity of empirical support for polypharmacy with second generation (atypical) antipsychotics (SGAs), especially in understudied populations...
- Changes over time in frontotemporal activation during a working memory task in patients with schizophreniaRobert Christian Wolf
Department of Psychiatry, University of Ulm, Leimgrubenweg 12 14, 89075 Ulm, Germany
Schizophr Res 91:141-50. 2007....
- Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to dateAlex S Cohen
Department of Psychology, University of Maryland, College Park, USA
Schizophr Bull 33:1201-12. 2007..The question of whether deficit patients exhibit a unique cognitive impairment profile will require a more sophisticated and rigorous examination of the neuropsychology of the deficit syndrome...
- How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophreniaJohn S Brekke
Schizophr Bull 33:1247-56. 2007....
- The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trialY Lecrubier
Pitié Salpétrière U 302 Hospital, Paris Cedex, France
Acta Psychiatr Scand 114:319-27. 2006..The aim of the study was to evaluate the efficacy of olanzapine (5 and 20 mg/day) over a 6-month period in chronic schizophrenic patients experiencing predominantly negative symptoms...
- Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity?Anil K Malhotra
Division of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, and Albert Einstein College of Medicine, United States
Schizophr Res 87:181-4. 2006..We tested the hypothesis that ziprasidone improves cognition in the absence of clinical improvement...
- Control group bias in randomized atypical antipsychotic medication trials for schizophreniaScott W Woods
Treatment Research Program, Department of Psychiatry and Biostatistics Division, Yale University School of Medicine, New Haven, Conn. 06519, USA
Arch Gen Psychiatry 62:961-70. 2005..or schizoaffective disorder that reported baseline and intent-to-treat end point change values for the Brief Psychiatric Rating Scale. DATA EXTRACTION: Study number, sample size, reported dosage for each arm, trial duration, percentage ..
- Demographic, clinical, and neurocognitive predictors of quality of life in schizophrenia patients receiving conventional neurolepticsTeresa L Sota
Neurobehavioral Research Unit, St. Michael's Hospital, Toronto, Ontario, Canada
Compr Psychiatry 45:415-21. 2004..Rehospitalization was related only to demographic data and previous hospital admissions. The findings support the predictive value of selected aspects of neurocognition in relation to a subjective outcome domain in schizophrenia...
- Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studiesJan Volavka
The Nathan Kline Institute and New York University, 140 Old Orangeburg Road, Orangeburg, N Y 10962, USA
J Clin Psychiatry 66:1362-6. 2005..The objective was to determine the effects of aripiprazole on hostility...
- Abnormal neurological signs at the onset of psychosisRussell E Scheffer
Department of Psychiatry and Behavioral Medicine, The Medical College of Wisconsin, Milwaukee, WI, USA
Schizophr Res 70:19-26. 2004....
- Neuropsychological functions predict 1- and 3-year outcome in first-episode psychosisR Carlsson
Department of Psychology, Lund University, Lund, Sweden
Acta Psychiatr Scand 113:102-11. 2006..To examine neuropsychological performance as a possible predictor of course and outcome in first-episode psychotic (FEP) patients...
- The effects of clozapine and risperidone on spatial working memory in schizophreniaSusan R McGurk
Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Pl, New York, NY 10029, USA
Am J Psychiatry 162:1013-6. 2005..The purpose of this investigation was to evaluate the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia...
- Clozapine with amisulpride for refractory schizophreniaMarcus W Agelink
Am J Psychiatry 161:924-5. 2004
- Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naïve patients with schizophreniaS Kristian Hill
Center for Cognitive Medicine, Department of Psychiatry M C 913, University of Illinois at Chicago, 912 South Wood Street, Suite 235, Chicago, IL 60612, USA
Schizophr Res 68:49-63. 2004..Relatively static and generalized neuropsychological dysfunction, evident from illness onset, is consistent with neurodevelopmental rather than neurodegenerative models of schizophrenia...
- Facial recognition deficits and cognition in schizophreniaGabriele Sachs
Department of Psychiatry, University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
Schizophr Res 68:27-35. 2004..001). The study did not reveal a specific deficit for emotion recognition in schizophrenia. These findings lend support to the notion that difficulties in emotion recognition are associated in schizophrenia with key cognitive deficits...
- Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidonePo See Chen
Department of Psychiatry, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Psychiatry Clin Neurosci 58:168-72. 2004..Both RIS and 9-OH-RIS have an impact on the CPT performance of schizophrenic patients. Optimal active moiety plasma concentration for best cognitive performance needs further study...
- Open label study of the effect of amantadine on weight gain induced by olanzapineWon-Myong Bahk
Department of Psychiatry, College of Medicine, Catholic University of Korea, Seoul, Korea
Psychiatry Clin Neurosci 58:163-7. 2004..All subjects were evaluated by weight, body mass index (BMI), the Brief Psychiatric Rating Scale (BPRS), and the Extrapyramidal Symptom Rating Scale (ESRS) before and after the use of amantadine in ..
- Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteersJuan Francisco Artaloytia
Hospital Universitario 12 de Octobre, Madrid, Spain
Am J Psychiatry 163:488-93. 2006..Risperidone caused significantly more negative signs and symptoms than placebo on the Brief Psychiatric Rating Scale (BPRS), the SANS, the Subjective Deficit Syndrome Scale total score, and the analog scale for ..
- Neurocognitive and social cognitive correlates of formal thought disorder in schizophrenia patientsKenneth L Subotnik
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, 90095 6968, USA
Schizophr Res 85:84-95. 2006..This pattern of findings is consistent with the view that neurocognitive and, possibly, social cognitive deficits underlie these two aspects of formal thinking disturbance in schizophrenia...
- The utility of intramuscular ziprasidone in the management of acute psychotic agitationAlan J Mendelowitz
Department of Psychiatry, Albert Einstein University, Bronx, New York, USA
Ann Clin Psychiatry 16:145-54. 2004..This report focuses on the pharmacology, clinical efficacy, and tolerability of IM ziprasidone, and provides an overview of the utility of other commonly used antipsychotics in the management of acute psychotic agitation...
- A six-factor model of cognition in schizophrenia and related psychotic disorders: relationships with clinical symptoms and functional capacityJulie Akiko Gladsjo
Department of Psychiatry, University of California, San Diego 92161, USA
Schizophr Bull 30:739-54. 2004..A simultaneous confirmatory factor analysis using the original sample and a group of healthy subjects (n = 131) demonstrated that the six-factor model of cognition was generalizable and applied equally well to both groups...
- Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophreniaGeorge M Simpson
Department of Psychiatry and the Behavioral Sciences, LAC USC Medical Center, IRD RM 204, Psychiatric Outpatient Clinic, 2020 Zonal Ave, Los Angeles, CA 90033, USA
Am J Psychiatry 162:1535-8. 2005..The authors' goal was to compare the efficacy and tolerability of 6 months' treatment with flexible-dose ziprasidone and olanzapine in patients with schizophrenia or schizoaffective disorder...
- Symptom rating scales and outcome in schizophreniaAnn M Mortimer
Department of Psychiatry, University of Hull
Br J Psychiatry Suppl 50:s7-14. 2007..Symptom rating scales are now well established in schizophrenia research but their scores are not the same as outcome...
- Socioeconomic status of origin and the clinical expression of SchizophreniaBrooke Parrott
Department of Psychological and Brain Sciences, University of Louisville, KY 40292, USA
Schizophr Res 75:417-24. 2005..Possible interactions between socioeconomic status and sex of patient are discussed, as well as suggestions for further study...
- Clinical effects of a randomized switch of patients from clozaril to generic clozapineJ C Kluznik
Saint Peter Regional Treatment Center, Forensic Division, St Peter, Minn 50682, USA
J Clin Psychiatry 62:14-7; discussion 23-4. 2001..Efficacy was measured with the Clinical Global Impressions-Improvement (CGI-I) scale, the Brief Psychiatric Rating Scale (BPRS), and the Beck Depression Inventory (BDI)...
- Subjective cognitive dysfunction in first-episode and chronic schizophrenic patientsS Moritz
Clinic for Psychiatry and Psychotherapy, University Clinic Hamburg-Eppendorf, Hamburg, Germany
Compr Psychiatry 42:213-6. 2001..In marked contrast to a Kraepelinian view of schizophrenia, the present data confirm previous studies conducted with objective neuropsychological tests that schizophrenia is a neurodevelopmental rather than a neurodegenerative disorder...
- Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trialJ C Gomez
Eli Lilly Spain, Alcobendas, Madrid
J Clin Psychiatry 62:6-11. 2001..An analysis of variance was used to compare treatment effects on efficacy measurements including the Brief Psychiatric Rating Scale (BPRS; scored 0-6) and the Positive and Negative Syndrome Scale (total, positive subscale, and ..
- Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophreniaB J Kinon
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Ind 46285, USA
J Clin Psychiatry 62:17-21. 2001..olanzapine (5-20 mg/day) or haloperidol (5-20 mg/day) assessed the treatment effects on agitation (Brief Psychiatric Rating Scale [BPRS] agitation score) and positive symptoms (BPRS positive symptom score)...
- Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugsMassimo C Mauri
Clinical Psychiatry, University of Milan, Clinical Neuropsychopharmacology Unit, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via F Sforza 35, 20122 Milano, Italy
Schizophr Res 99:7-12. 2008..The Brief Psychiatric Rating Scale (BPRS), Extrapyramidal Side Effects Rating Scale (EPSE) and Anticholinergic Rating Scale (ACS) were ..
- Comparison of clozapine response for inpatients in the research setting versus routine clinical practiceDouglas L Boggs
Maryland Psychiatric Research Center, School of Medicine, University of Maryland Baltimore, Baltimore, MD 21228, USA
Psychiatr Q 79:111-9. 2008..This study compares patient characteristics and treatment response between inpatients treated with clozapine in a research setting as compared to those initiated on clozapine during routine inpatient treatment...
- Psychopathology and neuropsychological impairments in deficit and nondeficit schizophrenia of Chinese originXiang Wang
The Medical Psychological Research Center, Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
Psychiatry Res 158:195-205. 2008..Schizophrenia patients completed the Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Negative Symptoms (SANS) and Scale for the Assessment of Positive ..
- Deficits in neurocognition, theory of mind, and social functioning in patients with schizophrenic disorders: are they related?Maryse Badan Bâ
Division of Adult Psychiatry, Department of Psychiatry, Early Psychosis Program JADE, University Hospitals of Geneva, Geneva, Switzerland
J Nerv Ment Dis 196:153-6. 2008..The latter were the only 2 related to manic-hostility and negative symptoms subscores of Brief Psychiatric Rating Scale. Our findings suggest that there is no direct relation between neurocognitive impairments and social ..
- Assessment of medication management ability in middle-aged and older adults with bipolar disorderColin A Depp
Department of Psychiatry, University of California, San Diego, CA, USA
J Clin Psychopharmacol 28:225-9. 2008..correlation was seen between MMAA scores and the DRS Total score, but not with age, education, Brief Psychiatric Rating Scale, Hamilton Depression Rating Scale, number of psychiatric medications, or medical conditions...
- Predictors of aggression on the psychiatric inpatient serviceMark R Serper
Department of Psychology, Hofstra University, Hempstead, NY 11549, USA
Compr Psychiatry 46:121-7. 2005..The need for relating predictors of specific types of aggressiveness in schizophrenia is discussed...
- Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparisonJ M Kane
Department of Psychiatry, Hillside Hospital, Glen Oaks, NY 11004, USA
Arch Gen Psychiatry 58:965-72. 2001..hostile-suspiciousness, anxiety-depression, thought disturbance, and total score measured on the Brief Psychiatric Rating Scale. No differences were detected in negative symptoms using the Brief Psychiatric Rating Scale or the ..
- Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programmeMarie Josée Poulin
Centre Hospitalier Affilie Universitaire De Quebec, Hôpital de l Enfant Jésus and Centre Hospitalier Robert Giffard, Quebec City, Quebec, Canada
Aust N Z J Psychiatry 41:980-9. 2007....
- Frontal Systems Behavior Scale in schizophrenia: relationships with psychiatric symptomatology, cognition and adaptive functionDawn I Velligan
Department of Psychiatry, University of Texas Health Science Center at San Antonio, MS 7792, 7300 Floyd Curl Drive, San Antonio 78229, USA
Psychiatry Res 113:227-36. 2002..differential relationships were found for apathy and disinhibition with symptoms as rated from the Brief Psychiatric Rating Scale and with cognitive variables including Trails B and verbal fluency scores...
- Relation of neurological soft signs to psychiatric symptoms in schizophreniaVijay A Mittal
Emory University, Department of Psychology, 235 Dental Building, 1462 Clifton Road, Atlanta, GA 30322, United States
Schizophr Res 94:37-44. 2007..The present study tests the associations between NSS and schizophrenia symptomatology and examines NSS as a potential marker for predicting treatment response...
- Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medicationsIoulia Savina
Department of Psychology, Queen s University, Kingston ON, Canada, K7L 3N6
Schizophr Res 94:128-38. 2007..We concluded that ToM performance of schizophrenic patients is influenced by the antipsychotic they are taking. Our results suggest that olanzapine or clozapine but not typicals or risperidone may improve or protect ToM ability...
- Correlations between negative symptoms and peripheral G protein levels in mononuclear leukocytes of deficit and nondeficit schizophrenics. Preliminary resultsPalmiero Monteleone
Department of Psychiatry, University of Naples S U N, Largo Madonna delle Grazie, 80138 Naples, Italy
Eur Arch Psychiatry Clin Neurosci 252:214-8. 2002..These results must be regarded as preliminary because of the possible interference of antipsychotic drugs on the explored parameters...
- Galantamine for the treatment of cognitive impairments in people with schizophreniaRobert W Buchanan
Department of Psychiatry, University of Maryland, Baltimore, MD, USA
Am J Psychiatry 165:82-9. 2008....
- Stability of set-shifting and planning abilities in patients with schizophreniaPhilip J Tyson
School of Health and Social Sciences, University of Gloucestershire, Francis Close Hall Campus, Swindon Road, Cheltenham, Gloucestershire, GL50 4AZ, UK
Psychiatry Res 129:229-39. 2004..This study accords with the presence of executive processing deficits in schizophrenia that are stable across time...
- Comparison of older patients with bipolar disorder and schizophrenia/schizoaffective disorderSanjay Gupta
Department of Psychiatry, Olean General Hospital, Olean, NY, USA
Am J Geriatr Psychiatry 15:627-33. 2007..The aim of this cross-sectional study was to explore differences in measures of symptoms and cognition, side effects, and functional impairment between older patients with schizophrenia and bipolar disorder...
- Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episodeJoseph Peuskens
Universitair Psychiatrisch Centrum Katholieke Universiteit Leuven, Campus St Jozef Kortenberg, Leuvensesteenweg 517, 3070 Kortenberg, Belgium
Schizophr Res 95:169-73. 2007..Analysis of a 6-week open label study with olanzapine 5-20 mg in 306 patients with acute exacerbation, shows resolution to be a clinically meaningful measure and an achievable outcome for treatment of acute psychosis...
- Apathy and the processing of novelty in schizophreniaRobert M Roth
Neuropsychology Program, Department of Psychiatry, Dartmouth Medical School DHMC, One Medical Center Drive, Lebanon, New Hampshire, 03756 0001, USA
Schizophr Res 98:232-8. 2008..The present findings indicate that schizophrenia is associated with slowed information processing, but do not support the hypothesis that apathy in schizophrenia is associated with abnormal processing of novelty...
- High-frequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging studyG Hajak
Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany
Psychol Med 34:1157-63. 2004..In this context, disentangling of negative and depressive symptoms is of the utmost importance when understanding specific rTMS effects on schizophrenic symptoms...
- Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitationVincenzo Villari
Emergency Department, Psychiatric Emergency Service, S Giovanni Hospital, Corso Bramante 88, 10126 Turin, Italy
Prog Neuropsychopharmacol Biol Psychiatry 32:405-13. 2008..GENERAL METHODS: We recruited 101 patients with acute psychosis who were admitted at the Mental Health Department 1 South of Turin, Psychiatric Emergency Service of San Giovanni Battista Hospital, from June 2004 to June 2005...
- Cognitive correlates of schizophrenia signs and symptoms: I. Verbal communication disturbancesHoward Berenbaum
Department of Psychology, University of Illinois at Urbana Champaign, Champaign, IL 61820, United States
Psychiatry Res 159:147-56. 2008..Alogia and discourse coherence were differentially associated with performance on tasks measuring fluency, working memory, word finding abilities, and concentration/attention...
- One-year outcome after response to ECT in middle-aged and elderly patients with intractable catatonic schizophreniaKazumasa Suzuki
Department of Psychiatry, Tohoku University Graduate School of Medicine, Aoba ku, Sendai, Japan
J ECT 20:99-106. 2004..Thus, we conducted prospective studies on the short-term (phase 1 study) and long-term (phase 2 study) effects of acute ECT on intractable catatonic schizophrenia in middle-aged and elderly patients...
- Clozapine utilization and outcomes by race in a public mental health system: 1994-2000Deanna L Kelly
Maryland Psychiatric Research Center, University of Maryland, Baltimore 21228, USA
J Clin Psychiatry 67:1404-11. 2006..This study extends previous studies of clozapine by examining patient- and treatment-related factors that may help explain or eliminate reasons for differential prescribing...
- Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidolAkihito Suzuki
Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan
Ther Drug Monit 25:192-6. 2003..or homochlorcyclizine and 1 week after the discontinuation, together with clinical assessments by Brief Psychiatric Rating Scale (BPRS) and Udvalg for kliniske undersogelser (UKU) side effect rating scale...
- Short-term effect of ECT in middle-aged and elderly patients with intractable catatonic schizophreniaKazumasa Suzuki
Department of Psychiatry, Tohoku University Graduate School of Medicine, Sendai, Japan
J ECT 19:73-80. 2003..Thus, we conducted a prospective study of the short-term effect of acute ECT on middle-aged and elderly patients with intractable catatonic schizophrenia...
- The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysisD M McLoughlin
Section of Old Age Psychiatry, Institute of Psychiatry, London, UK
Health Technol Assess 11:1-54. 2007..To investigate if repetitive transcranial magnetic stimulation (rTMS) was as effective as electroconvulsive therapy (ECT) in treating major depressive episodes and to perform a cost-effectiveness analysis...
- Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidoneM Markianos
Athens University Medical School, Psychiatric Clinic, Eginition Hospital, Vass Sophias 74, 11528 Athens, Greece
Psychopharmacology (Berl) 157:55-9. 2001....
- Neuropsychiatric aspects of HIV disease progression: impact of traditional herbs on adult patients in ZimbabweMohamedi B Sebit
Department of Psychiatry, University of Zimbabwe Medical School, Avondale, Harare, Zimbabwe
Prog Neuropsychopharmacol Biol Psychiatry 26:451-6. 2002..Instruments used were the Brief Psychiatric Rating Scale (BPRS), Montgomery-Asberg Depression Rating Scale (MADRS), Structured Interview Diagnosis of Dementia ..
- [Causes and psychosocial consequences of schizophrenia: the opinions of patient's relatives]L Magliano
Istituto di Psichiatria, Università di Napoli SUN
Epidemiol Psichiatr Soc 9:113-25. 2000....
- Clozapine-induced weight gain predicts improvement in psychopathologyHerbert Y Meltzer
Department of Psychiatry, Psychiatric Hospital at Vanderbilt, Vanderbilt University School of Medicine, 1601 23rd Avenue South 306, Nashville, TN 37215, USA
Schizophr Res 59:19-27. 2003..The purpose of this study was to test the hypothesis that clozapine-induced weight gain is related to antipsychotic efficacy at 6 weeks and 6 months after adjusting for initial body weight and severity of illness...
- Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approachL Sauriol
Aventis Pharma Canada Inc, Laval, Quebec
Clin Ther 23:942-56. 2001..Meta-analysis is a useful method to assess the efficacy of newer antipsychotic drugs compared with older drugs or placebo. However, few trials directly compare novel drugs to each other...
- Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind studyMichael Kluge
Max Planck Institute of Psychiatry, Kraepelinstrasse 2 10, Munich, Germany
J Clin Psychopharmacol 27:662-6. 2007..study comparing abnormal eating behavior using a standardized scale, clinical efficacy using the Brief Psychiatric Rating Scale 0-6 and Clinical Global Impression-Severity scale, and tolerability of clozapine and olanzapine...
- Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography studyHubert H Fernandez
Department of Neurology, College of Medicine, University of Florida, FL, USA
Int J Neurosci 119:2196-205. 2009..The Clinical Global Impression Scale (CGIS), Brief Psychiatric Rating Scale (BPRS), and Unified Parkinson Disease Rating Scale (UPDRS) motor subscale were obtained...
- Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidolJ A Den Boer
University Hospital, Department of Biological Psychiatry, Utrecht, The Netherlands
Psychopharmacol Bull 26:99-107. 1990..Symptoms assessment was performed using the Brief Psychiatric Rating Scale (BPRS), the Clinical Global Impressions (CGI) and the Present State Examination (PSE)...
- Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazineS Bender
University of Essen, Clinic for Psychiatry and Psychotherapy, Germany
Pharmacopsychiatry 36:61-9. 2003..The aim of the study was to investigate the antipsychotic potential of trimipramine in a controlled clinical trial comparing its antipsychotic efficacy with that of a neuroleptic...
- Tolerability of remoxipride in the long term treatment of schizophrenia. An overviewA C Holm
Department of CNS Clinical Research, Astra Arcus AB, Sodertalje, Sweden
Drug Saf 8:445-56. 1993..Remoxipride was administered in daily doses of 75 to 600mg. The assessment tools were Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), Simpson and Angus scale, Abnormal Involuntary Movements ..
- A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophreniaX Y Zhang
Yale University School of Medicine, Neuropsychopharmacology Lab, New Haven, CT 06520 8066, USA
J Clin Psychiatry 62:878-83. 2001..The aim of this study was to determine the effectiveness and to evaluate the side effects of extract of Ginkgo biloba (EGb) plus haloperidol in chronic, treatment-resistant inpatients with schizophrenia...
- Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophreniaKazumasa Suzuki
Department of Psychiatry, Tohoku University Graduate School of Medicine, Sendai, Japan
Psychiatry Clin Neurosci 59:481-9. 2005..Clinical symptoms were evaluated by means of the Brief Psychiatric Rating Scale (BPRS) weekly for 48 weeks or until relapse...
- Further validation of the Chinese version of the Level of Expressed Emotion Scale for research and clinical useWai Tong Chien
The School of Nursing, Faculty of Health and Social Sciences, The Hong Kong Polytechnics University, Hung Hom, Kowloon, Hong Kong, China
Int J Nurs Stud 47:190-204. 2010..In Western countries this construct is used as an outcome measure of interventions for families of people with schizophrenia or other psychotic disorders, but the use of this construct in Chinese populations is somewhat limited...
- High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndromeHaggai Hermesh
Geha Psychiatric Hospital and Felsenstein Medical Research Center, Petah Tiqva, Israel
J Clin Psychopharmacol 22:252-6. 2002..transaminase (SGOT), and white blood cell count (WBC) during all non-NMS psychotic episodes (Brief Psychiatric Rating Scale 40) were averaged...
- Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trialSamarthji Lal
Douglas Hospital Research Centre, 6875 LaSalle Boulevard, Verdun, Montreal, Quebec
J Psychiatry Neurosci 31:271-9. 2006..We compared the effect of levomepromazine (LMP) with chlorpromazine (CPZ) in treatment-resistant schizophrenia (TRS)...
- Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up studyAntonio Ciapparelli
Department of Psychiatry, Neurobiology, Pharmacology, and Biotechnology, University of Pisa, Italy
J Clin Psychiatry 64:451-8. 2003..The aim of this study was to evaluate the long-term efficacy and safety of clozapine in patients with treatment-resistant schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features...
- Characteristics of trees drawn by patients with paranoid schizophreniaHiroyuki Inadomi
Department of Occupational Therapy, School of Health Sciences, Nagasaki University, Sakamoto, Nagasaki, Japan
Psychiatry Clin Neurosci 57:347-51. 2003..Differences in psychiatric symptoms as assessed using the Brief Psychiatric Rating Scale (BPRS) score were compared between patients with paranoid and non-paranoid schizophrenia...
- Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neurolepticsE Spina
Centers of Mental Health, Azienda USL 5, Messina, Italy
Psychopharmacology (Berl) 148:83-9. 2000..Monitoring plasma clozapine concentrations may play a useful role in the management of patients with schizophrenia, but information on the relationship between the plasma levels of the drug and response is still controversial...
- Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot studySilvio Bellino
Unit of Psychiatry, Department of Neuroscience, University of Turin, Turin, Italy
J Clin Psychiatry 67:1042-6. 2006..Sparse data are available on the use of quetia-pine in treating this disorder. The aim of the present study is to investigate efficacy and tolerability of quetia-pine in a group of patients with borderline personality disorder...
- Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trialRichard C Josiassen
The Arthur P Noyes Research Foundation, Norristown State Hospital, Norristown, PA 19401, USA
Am J Psychiatry 162:130-6. 2005..The authors evaluated the efficacy and safety of augmenting clozapine with risperidone in patients with treatment-resistant schizophrenia...
- Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophreniaHaya Ascher-Svanum
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
BMC Psychiatry 5:3. 2005..This study assessed the impact of acute treatment-emergent weight gain on clinical and functional outcomes of patients with schizophrenia by patient gender and antipsychotic treatment (olanzapine or haloperidol)...
- Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophreniaS Ulrich
Institute of Clinical Pharmacology, University Hospital, Otto von Guericke University, Magdeburg, Germany
Int Clin Psychopharmacol 14:219-28. 1999..Psychopathology was measured by the Brief Psychiatric Rating Scale and several subscales...
- A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late lifeB H Mulsant
Intervention Research Center for the Study of Late Life Mood Disorders, Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA
J Clin Psychiatry 62:597-604. 2001..To conduct the first randomized study comparing the efficacy of an antidepressant alone versus an antidepressant plus a neuroleptic in the treatment of late-life psychotic depression...
- Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective studyI Gaertner
Department of Psychiatry and Psychotherapy, University of Tuebingen, Germany
J Clin Psychopharmacol 21:305-10. 2001..Every 4 weeks, psychopathology was assessed by the Brief Psychiatric Rating Scale (BPRS), and plasma CZ and norclozapine levels were measured...
- Prazosin Treatment for Disruptive Agitation in Alzheimer's DiseaseElaine Peskind; Fiscal Year: 2009..Secondary outcome measures are the Brief Psychiatric Rating Scale (BPRS) total score, BPRS Agitation Factor, ADCS-Activities of Daily Living-19, and the Mini Mental ..
- Prazosin Treatment for Disruptive Agitation in Alzheimer's DiseaseElaine R Peskind; Fiscal Year: 2010..Secondary outcome measures are the Brief Psychiatric Rating Scale (BPRS) total score, BPRS Agitation Factor, ADCS-Activities of Daily Living-19, and the Mini Mental ..
- GLYCINE-KETAMINE INTERACTIONS IN HEALTHY SUBJECTSDEEPAK D SOUZA; Fiscal Year: 2002..Clinician Administered Dissociative Symptom Scale), negative and positive symptoms of psychosis (Brief Psychiatric Rating Scale), recall (Hopkins Verbal Learning Test) and working memory will be administered...
- ALZHEIMER'S IN LONG TERM PROPRANOLOL FOR AGITATIONElaine Peskind; Fiscal Year: 2003..Clinical Global Impression of Change score and change scores from baseline to last observation on the Brief Psychiatric Rating Scale and Neuropsychiatric Inventory. Cognition, functional status, and adverse events will also be assessed...
- Comorbid Substance Abuse and Long-Term Health Outcomes in SchizophreniaDEANNA KELLY; Fiscal Year: 2007..This will be an important step for improving the lives of people with schizophrenia. ..
- Cardiac-Related Mortality with Atypical AntipsychoticsDEANNA KELLY; Fiscal Year: 2005..This study is important as data on long-term health outcomes with atypical antipsychotics is lacking from the literature. ..
- 3/4 Collaboration to Advance Negative Symptom Assessment in SchizophreniaWilliam P Horan; Fiscal Year: 2010..This state-of-the art instrument will play a central role in the NIMH initiative to stimulate the development of new treatments aimed at reducing the disability associated with negative symptoms. ..
- Electrophysiological Correlates of Anhedonia in SchizophreniaWILLIAM HORAN; Fiscal Year: 2007....
- Interventions to Improve Functional Outcome, Persistent Symptoms in SchizophreniaDawn Velligan; Fiscal Year: 2009..We will compare 4 treatments to determine if this combined approach improves both symptoms and functioning for individuals with schizophrenia. ..
- Functional Brain Abnormalities in the Schizophrenia ProdromeDaniel Mathalon; Fiscal Year: 2007....
- Citicoline for Bipolar Disorder and Cocaine DependenceE Sherwood Brown; Fiscal Year: 2010..To conduct this trial we have assembled a research team with expertise in mood disorders, clinical trials, cocaine dependence, neuropsychological testing, and statistical analysis. ..
- Clozapine Treatment of Schizophrenic PatientsRobert Buchanan; Fiscal Year: 2006..The study will provide new information on the clinical utility of adjunctive risperidone in treatment-resistant patients who fail to adequately respond to clozapine. ..
- Quetiapine for Bipolar Disorder and Alcohol DependenceE Sherwood Brown; Fiscal Year: 2007..A research team with extensive experience in dual diagnosis, mood disorders, clinical trials, statistics, and alcohol dependence research has been assembled to conduct the trial. ..
- Clinical Center for the Parkinson Disease Neuroprotection Clinical TrialHubert Fernandez; Fiscal Year: 2006..abstract_text> ..
- Compensating for Cognitive Deficits in SchizophreniaDawn Velligan; Fiscal Year: 2005..abstract_text> ..
- CLOZAPINE TREATMENT OF SCHIZOPHRENIC OUTPATIENTSRobert Buchanan; Fiscal Year: 2000..These data may provide new information about clozapine's mechanism of action and the pathophysiology of schizophrenia. ..
- Reversing Corticosteroid-Induced Memory ImpairmentE Sherwood Brown; Fiscal Year: 2010..The findings will have implications for patients with major depressive disorder and the millions treated each year with prescription corticosteroids. ..
- Citicoline for Bipolar Disorder and Cocaine DependenceE Sherwood Brown; Fiscal Year: 2009..To conduct this trial we have assembled a research team with expertise in mood disorders, clinical trials, cocaine dependence, neuropsychological testing, and statistical analysis. ..
- Liability Markers for Deficit Schizophrenia?L Hong; Fiscal Year: 2004..We plan to use the preliminary data collected from this grant support to guide our full-scale search for phenotypic markers specifically associated with the liability for deficit schizophrenia and subsequent molecular genetic studies. ..
- MEDICATION ADHERENCE AND OUTCOMES IN SCHIZOPHRENIADawn Velligan; Fiscal Year: 2004..Moreover, we hypothesize that compliance and functioning will return to baseline levels six months after discontinuation of treatment. ..
- Quetiapine for Bipolar Disorder and Alcohol DependenceE Sherwood Brown; Fiscal Year: 2010..A research team with extensive experience in dual diagnosis, mood disorders, clinical trials, statistics, and alcohol dependence research has been assembled to conduct the trial. ..
- Neural Oscillatory Biomarkers for Genetics and Animal Models of SchizophreniaL Elliot Hong; Fiscal Year: 2010....
- Shared Neural Circuitry in Comorbid Schizophrenia and Nicotine AddictionL Elliot Hong; Fiscal Year: 2010....
- Smoking Cessation and Smoking Relapse Prevention in Patients with SchizophreniaA Eden Evins; Fiscal Year: 2010..Participants will then discontinue study medications and enter a 3-month follow up. The primary outcome measure will be 7-day point prevalence abstinence rate at 12 months in the intervention vs. placebo groups. ..
- Glycine Transport Inhibition for Nicotine Dependence in SchizophreniaA Evins; Fiscal Year: 2009....
- CLOZAPINE TREATMENT OF SCHIZOPHRENIC OUTPATIENTSRobert Buchanan; Fiscal Year: 1993..These data may provide new information about clozapine's mechanism of action and the pathophysiology of schizophrenia...
- NICOTINE AND SMOKING CESSATION IN SCHIZOPHRENIAA Evins; Fiscal Year: 2005....
- fMRI of Eye Movement Phenotype in SchizophreniaL Hong; Fiscal Year: 2007....
- Glycine Transport Inhibition for Nicotine Dependence in SchizophreniaA Evins; Fiscal Year: 2006....
- Advanced Centers for Interventions and Services ResearchRobert Buchanan; Fiscal Year: 2007....
- Identifying molecular path of behavioural phenotype in schizophreniaL Hong; Fiscal Year: 2007..This project aims to identify genes and gene products associated with one of these core deficits called eyetracking abnormality in schizophrenia so that drugs can be developed to treat these core physiological and cognitive deficits. ..
- Smoking Cessation and Smoking Relapse Prevention in Patients with SchizophreniaA Evins; Fiscal Year: 2007..Participants will then discontinue study medications and enter a 3-month follow up. The primary outcome measure will be 7-day point prevalence abstinence rate at 12 months in the intervention vs. placebo groups. ..
- Interventions for Adherence to Oral Antipsychotic Medications in SchizophreniaDawn Velligan; Fiscal Year: 2007..The public health implications include effective disease management, maximizing long-term outcomes, and containing health care costs for schizophrenia. ..